Browse the corpus

REFERENCES Aghajanian C, Blank SV, Goff BA, et al, “OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer,” J Clin Oncol, 2012, 30(17):2039-45. [PubMed 22529265 ] Agulnik M, Yarber JL, Okuno SH, et al, “An Open-Label, Multicenter, Phase II Study of Bevacizumab for the Treatment of Angiosarcoma and Epithelioid Hemangioendotheliomas,” Ann Oncol , 2013, 24(1):257-63. [PubMed 22910841 ] Allegra CJ, Yothers G, O'Connell MJ, et al, “Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer,” J Clin Oncol , 2009, 27(20):3385-90. [PubMed 19414665 ] Avery RL, Pieramici DJ, Rabena MD, et al, “Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration,” Ophthalmology , 2006, 113(3):363-72. [PubMed 16458968 ] Azad NS, Aragon-Ching JB, Dahut WL, et al, “Hand-Foot Skin Reaction Increases With Cumulative Sorafenib Dose and With Combination Anti-Vascular Endothelial Growth Factor Therapy,” Clin Cancer Res , 2009, 15(4):1411-16. [PubMed 19228742 ] Bansal N and Hoffman M, “Bladder Perforation in a Patient With Recurrent Epithelial Ovarian Cancer After Treatment With Bevacizumab,” Gynecol Oncol , 2011, 120(2):313-4. [PubMed 21055796 ] Bashshur AF, Bazarbachi A, Schakal A, et al, “Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-Related Macular Degeneration,” Am J Ophthalmol , 2006, 142(1):1-9. [PubMed 16815245 ] Bracarda S, Bellmunt J, Melichar B, et al, "Overall Survival in Patients With Metastatic Renal Cell Carcinoma Initially Treated With Bevacizumab Plus Interferon-α2a and Subsequent Therapy With Tyrosine Kinase Inhibitors: A Retrospective Analysis of the Phase III AVOREN Trial," BJU Int , 2011, 107(2):214-9. [PubMed 20942831 ] Burger RA, Brady MF, Bookman MA, et al, “Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer,” N Engl J Med , 2011, 365(26):2473-83. PMID: 22204724 [PubMed 22204724 ]

Bracarda S, Bellmunt J, Melichar B, et al, "Overall Survival in Patients With Metastatic Renal Cell Carcinoma Initially Treated With Bevacizumab Plus Interferon-α2a and Subsequent Therapy With Tyrosine Kinase Inhibitors: A Retrospective Analysis of the Phase III AVOREN Trial," BJU Int , 2011, 107(2):214-9. [PubMed 20942831 ] Burger RA, Brady MF, Bookman MA, et al, “Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer,” N Engl J Med , 2011, 365(26):2473-83. PMID: 22204724 [PubMed 22204724 ] Burger RA, Sill MW, Monk BJ, et al, “Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study,” J Clin Oncol , 2007, 25(33):5165-71. [PubMed 18024863 ] Cannistra SA, Matulonis UA, Penson RT, et al, “Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer,” J Clin Oncol , 2007, 25(33):5180-6. [PubMed 18024865 ] Christodoulou C, Pervena A, Klouvas G, et al, "Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently Than Bisphosphonates Alone," Oncology , 2009, 76(3):209-11. [PubMed 19212145 ] Choueiri TK, Mayer EL, Je Y, et al, “Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab,” J Clin Oncol , 2011, 29(6):632-8. [PubMed 21205755 ] Cloughesy TF, Prados MD, Wen PY, et al, “A Phase II, Randomized, Non-Comparative Clinical Trial of the Effect of Bevacizumab (BV) Alone or in Combination With Irinotecan (CPT) on 6-Month Progression Free Survival (PFS6) in Recurrent, Treatment-Refractory Glioblastoma (GBM),” J Clin Oncol , 2008, 26(Supp):2010B [abstract 2010b from 2008 ASCO Annual Meeting]. Erinjeri JP, Fong AJ, Kemeny NE, et al, “Timing of Administration of Bevacizumab Chemotherapy Affects Wound Healing After Chest Wall Port Placement,” Cancer , 2011, 117(6):1296-301. [PubMed 21381016 ] Escudier B, Pluzanska A, Koralewski P, et al, “Bevacizumab Plus Interferon Alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial,” Lancet , 2007, 370(9605):2103-11. [PubMed 18156031 ] Estilo CL, Fornier M, Farooki A, et al, "Osteonecrosis of the Jaw Related to Bevacizumab," J Clin Oncol , 2008, 26(24):4037-8. [PubMed 18711196 ]

Escudier B, Pluzanska A, Koralewski P, et al, “Bevacizumab Plus Interferon Alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial,” Lancet , 2007, 370(9605):2103-11. [PubMed 18156031 ] Estilo CL, Fornier M, Farooki A, et al, "Osteonecrosis of the Jaw Related to Bevacizumab," J Clin Oncol , 2008, 26(24):4037-8. [PubMed 18711196 ] Feldman DR, Baum MS, Ginsberg MS, et al, “Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma,” J Clin Oncol , 2009, 27(9):1432-9. [PubMed 19224847 ] Feldman DR, Ginsberg MS, Baum M, et al, “Phase I Trial of Bevacizumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma,” J Clin Oncol , 2008, 26(Supp):5100 [abstract 5100 from 2008 ASCO Annual Meeting]. Glusker P, Recht L, and Lane B, “Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab,” N Engl J Med , 2006, 354(9):980-2. [PubMed 16510760 ] Greuter S, Schmid F, Ruhstaller T, et al, "Bevacizumab-Associated Osteonecrosis of the Jaw," Ann Oncol , 2008, 19(12):2091-2. [PubMed 18977851 ] Gray R, Bhattacharya S, Bowden C, et al, “Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer,” J Clin Oncol , 2009, 27(30):4966-72. [PubMed 19720913 ] Gupta S, Parsa VB, Heilbrun LK, et al, “Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction,” Anticancer Drugs , 2011, 22(8):794-800. [PubMed 21799472 ] Johnson DH, Fehrenbacher L, Novotny WF, et al, “Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,” J Clin Oncol , 2004, 22(11):2184-91. [PubMed 15169807 ] Kreisl TN, Kim L, Moore K, et al, “Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma,” J Clin Oncol , 2009, 27(5):740-5. [PubMed 19114704 ] Leighl NB, Bennouna J, Yi J, et al, "Bleeding Events in Bevacizumab-Treated Cancer Patients Who Received Full-Dose Anticoagulation and Remained on Study," Br J Cancer , 2011, 104(3):413-8. [PubMed 21245868 ]

Kreisl TN, Kim L, Moore K, et al, “Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma,” J Clin Oncol , 2009, 27(5):740-5. [PubMed 19114704 ] Leighl NB, Bennouna J, Yi J, et al, "Bleeding Events in Bevacizumab-Treated Cancer Patients Who Received Full-Dose Anticoagulation and Remained on Study," Br J Cancer , 2011, 104(3):413-8. [PubMed 21245868 ] Leighl NB, Zatloukal P, Mezger J, et al, "Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL), J Thorac Oncol , 2010, 5(12):1970-6. [PubMed 20978447 ] Lou E, Turner S, Sumrall A, et al, “Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma,” J Clin Oncol , 2011, 29(28):e739-42. [PubMed 21900098 ] Miles D, Chan A, Dirix LY, et al, "Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,” J Clin Oncol , 2010, 28(20):3239-47. [PubMed 20498403 ] Miller KD, "E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer," Clin Breast Cancer , 2003, 3(6):421-2. [PubMed 12636887 ] Miller KD, Chap LI, Holmes FA, et al, "Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer," J Clin Oncol , 2005, 23(4):792-9. [PubMed 15681523 ] Miller K, Wang M, Gralow J, et al, “Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer,” N Engl J Med , 2007, 357(26):2666-76. [PubMed 18160686 ] Monk BJ, Choi DC, Pugmire G, et al, “Activity of Bevacizumab (rhuMAB VEGF) in Advanced Refractory Epithelial Ovarian Cancer,” Gynecol Oncol , 2005, 96(3):902-5. [PubMed 15721449 ] Monk BJ, Sill MW, Burger RA, et al, "Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study," J Clin Oncol , 2009, 27(7):1069-74. [PubMed 19139430 ] Nalluri SR, Chu D, Keresztes R, et al, “Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-Analysis,” JAMA , 2008, 300(19): 2277-85. [PubMed 19017914 ]

Monk BJ, Sill MW, Burger RA, et al, "Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study," J Clin Oncol , 2009, 27(7):1069-74. [PubMed 19139430 ] Nalluri SR, Chu D, Keresztes R, et al, “Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-Analysis,” JAMA , 2008, 300(19): 2277-85. [PubMed 19017914 ] Ozcan C, Wong SJ, and Hari P, “Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab,” N Engl J Med , 2006, 354(9):981-2. [PubMed 16514715 ] Park MS, Patel SR, Ludwig JA, et al, “Activity of Temozolomide and Bevacizumab in the Treatment of Locally Advanced, Recurrent, and Metastatic Hemangiopericytoma and Malignant Solitary Fibrous Tumor,” Cancer , 2011, 117(21):4939-47. [PubMed 21480200 ] Perren TJ, Swart AM, Pfisterer J, et al, “A Phase 3 Trial of Bevacizumab in Ovarian Cancer,” N Engl J Med , 2011, 365(26):2484-96. [PubMed 22204725 ] Polyzos A, Kalbakis K, Kentepozidis N, et al, “Salvage Treatment In Metastatic Breast Cancer With Weekly Paclitaxel and Bevacizumab,” Cancer Chemother Pharmacol , 2011, 68(1):217-23. [PubMed 20922389 ] Ranpura V, Hapani S, and Wu S, “Treatment-Related Mortality With Bevacizumab in Cancer Patients,” JAMA , 2011, 305(5):487-94. [PubMed 21285426 ] Reck M, von Pawel J, Zatloukal P, et al, “Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAil,” J Clin Oncol , 2009, 27(8):1227-34. [PubMed 19188680 ] Reidy DL, Chung KY, Timoney JP, et al, “Bevacizumab 5 mg/kg Can be Infused Safely over 10 minutes,” J Clin Oncol , 2007, 25(19):2691-5. [PubMed 17602073 ] Rini BI, Halabi S, Rosenberg JE, et al, “Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206,” J Clin Oncol , 2008, 26(33):5422-8. [PubMed 18936475 ] Robert NJ, Dieras V, Glaspy J, et al, “RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab (B) for First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC),” J Clin Oncol , 2009, 27(15s):1005 [abstract 1005 from 2009 ASCO Annual Meeting]

Robert NJ, Dieras V, Glaspy J, et al, “RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab (B) for First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC),” J Clin Oncol , 2009, 27(15s):1005 [abstract 1005 from 2009 ASCO Annual Meeting] Saltz LB, Clarke S, Díaz-Rubio E, et al, “Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,” J Clin Oncol , 2008, 26(12):2013-9. [PubMed 18421054 ] Sandler A, Gray R, Perry MC, et al, “Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer,” N Engl J Med , 2006, 355(24):2542-50. [PubMed 17167137 ] Sane DC, Anton L, and Brosnihan KB, “Angiogenic Growth Factors and Hypertension,” Angengenesis , 2004, 7(3):193-201. Scappaticci FA, Skillings JR, Holden SN, et al, “Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated With Chemotherapy and Bevacizumab,” J Natl Cancer Inst , 2007, 99(16):1232-9. [PubMed 17686822 ] Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al, “Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme,” J Clin Oncol , 2007, 25(30):4722-9. [PubMed 17947719 ] Wagner AD, Thomssen C, Haerting J, et al, “Vascular-Endothelial-Growth-Factor (VEGF) Targeting Therapies for Endocrine Refractory or Resistant Metastatic Breast Cancer,” Cochrane Database Syst Rev , 2012, 7:CD008941. [PubMed 22786517 ] Yang JC, Haworth L, Sherry RM, et al, “A Randomized Trial of Bevacizumab, An Antivascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer,” N Engl J Med , 2003, 349(5):427-34. [PubMed 12890841 ] Zhu J, Sharma DB, Gray SW, et al, “Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Non-Small Cell Lung Cancer,” JAMA, 2012, 307(15):1593-601. [PubMed 22511687 ] Topic 8683 Version 42.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]